Taro Rejects Sun Pharma’s Settlement Offer; Suggests Shareholder Referendum
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Israeli generic drug maker Taro has rejected Sun Pharma's proposal for a merger at a value of $9.50 per share or increase the offer price for non-promoter shares to $9 for every ordinary share. In a letter written to Sun Pharma's Chairman and Managing Director Dilip Shanghvi, Taro Chairman Barrie Levitt said the Taro board of directors "did not view the two options" set forth in the proposal as constructive or even "in the ballpark
You may also be interested in...
Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline
MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court
Taro’s Merger Proposal At $15 A Share “Outrageous,” Sun Says; Extends Offer Deadline
MUMBAI - The war of words between Sun Pharmaceutical and Israeli drug maker Taro has intensified as the two companies exchange proposals and counter-proposals for a merger as directed by Israel's Supreme Court
Sun Pharma Buys Chattem Chemicals To Augment Its Controlled Substances Business
MUMBAI - The global economic downturn is throwing up acquisition possibilities for Indian pharmaceutical companies. India's Sun Pharma has lapped up U.S. based Chattem Chemicals, a registered narcotic API importer and producer based in Chattanooga, Tenn., for an undisclosed amount